Coherus recasts FY 2024/2023 financials for UDENYCA divestiture as discontinued operations

Coherus Oncology, Inc.

UDENYCA sale to Intas completed April 11, 2025 for $483.4M upfront cash including $118.4M inventory.
Company eligible for two additional $37.5M earn-out payments.
Recast financials for FY 2024 and 2023 show biosimilar businesses (UDENYCA, YUSIMRY, CIMERLI) as discontinued operations.
Recast is for incorporation into a Form S-3 registration statement filed Nov 13, 2025.
No other events after 2024 10-K filing are reflected except discontinued ops presentation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.